September 20th, 2021 | 12:05 CEST
Valneva, Cardiol Therapeutics, BioNTech - Recurring businesses
The vaccination rate is stalling. Around 4 million out of 24 million people over the age of 60 are still unvaccinated. Politicians led by Health Minister Jens Spahn have now launched a vaccination campaign week to get more people immunized against the coronavirus. The proportion of vaccinated people in Germany is still too low to prevent a new Corona wave and a possible resulting overload of the healthcare system. Meanwhile, vaccine producers are already working on the approval of booster shots. Profits should continue to bubble up for a long time.
time to read: 3 minutes
|
Author:
Stefan Feulner
ISIN:
VALNEVA SE EO -_15 | FR0004056851 , CARDIOL THERAPEUTICS | CA14161Y2006 , BIONTECH SE SPON. ADRS 1 | US09075V1026
Table of contents:
Author
Stefan Feulner
The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.
Tag cloud
Shares cloud
Cardiol Therapeutics - Milestone
The new Nasdaq-listed biotech Company Cardiol Therapeutics is currently accompanied by consistently positive news. And since the emergence of the SARS-CoV-2 virus, the research work of the Canadians has been more important than ever. Cardiol Therapeutics focuses on producing pharmaceutical cannabidiol (CBD) products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. Concerning vaccinations, inflammation of the heart muscle and pericardium occurred in the aftermath of vaccinations with mRNA vaccines, particularly in younger people.
The blockbuster product CardiolRx, a highly purified and concentrated oral cannabidiol formulation, has now recently received clearance from the FDA for an IND (Investigational New Drug) application for a Phase II clinical trial in acute myocarditis. The study is expected to enroll 100 patients in clinical centers in the United States and Europe. The IND approval represents another important milestone in pursuing new treatment options for patients with inflammatory heart disease. Results from the Phase II trial are expected to be announced as early as the first quarter of 2023. If the trial goes through smoothly, valuations, currently at a market cap of EUR 159.16 million, are expected to skyrocket.
The Nasdaq listing should already result in greater attention to the stock. The share price is quoted at CAD 5.40 on the home exchange in Toronto. The analysts of GBC Research already assign a price target of CAD 17.49.
Valneva - Battle for customers
Good tolerability, few, at least known, side effects and long-term studies carried out show the advantages of a classic inactivated vaccine over novel mRNA gene therapeutics. With these advantages, Valneva wanted to enter the market with its vaccine called VLA2001, which is currently in the third phase, and lure more vaccine skeptics in front of the stove. Here, Valneva plans to release more clinical trial data in October.
However, the French received a bitter blow with the withdrawal of their only customer, the British government. Now hopes rest on talks with the European Union. Unlike the British, the EU is showing further interest in the vaccine. At the level in the area around EUR 11, the horror news now seems to be slowly digested. Interested investors aware of the risk should the EU also lose interest in the inactivated vaccine are offered an entry opportunity at this level. If a customer is acquired, the stock market value is currently EUR 1.05 billion, providing a multiplication opportunity.
BioNTech - Ahead of the competition
The sparrows were already whistling it from the rooftops. The vaccine Comirnaty of the German Company BioNTech and its US partner Pfizer was able to achieve partial success at the advisory committee of the regulatory authority and, at least for a short time, to distance itself from its most significant competitor Moderna. After an advisory meeting on booster vaccinations, the latter announced that the application to recommend booster vaccinations for all persons 16 years of age and older would not be endorsed.
On the other hand, nothing stands in the way of booster vaccinations for people 65 and older and those with pre-existing conditions. These people should receive a booster vaccination with Comirnaty at an interval of six months after the last vaccination. A booster has also been made available for healthcare workers and other professions with an increased risk of contact. The FDA now plans to make a final decision soon. However, it can be assumed that the regulatory authority will follow the view of the advisory committee.
The share corrected by around 3% in trading after the announcement was published. Due to positive news flow, which is expected to remain, a breakout above the sideways trend formed early August at around USD 375 seems likely.
The topic of vaccines will continue to occupy society and the capital market for a long time to come. While BioNTech is likely to continue its winning streak, Valneva is a top or bottom play. Cardiol Therapeutics offers high long-term potential in the field of heart disease.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
